You are here

Novartis

Novartis powers Notch cancer biotech Ayala to $30M series B

Fierce Biotech

Wed, 05/29/19 - 10:28 am

Ayala Pharmaceuticals

adenoid cystic carcinoma

FDA Approves First NDA Under Real-Time Oncology Review Pilot

RAPS.org

Tue, 05/28/19 - 11:15 pm

Real Time Oncology Review

Novartis gets FDA nod for advanced breast-cancer treatment

Marketwatch

Sun, 05/26/19 - 11:19 am

advanced breast cancer

Novartis on goal to hit mid-30s margins by 2022

BioCentury

Sun, 05/26/19 - 11:15 am

Novartis gene therapy approved, but will come at cost of more than $2 million

Biopharma Dive

Fri, 05/24/19 - 11:45 pm

Novartis’ inhaled asthma combo QVM149 succeeds in two phase 2 trials

Pharmaceutical Business Review

Fri, 05/24/19 - 10:34 am

clinical trials

Novartis chief Vas Narasimhan wants you to know about the '25-plus’ blockbusters he has in the pipeline

Endpoints

Thu, 05/23/19 - 12:46 pm

Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range

Yahoo/Reuters

Thu, 05/23/19 - 09:48 am

Novartis' asthma triplet beats GSK's Advair in phase 2 trial

Fierce Pharma

Wed, 05/22/19 - 10:51 am

clinical trials

Verily lures major pharmas with promise of speedier clinical research

BioPharma Dive

Tue, 05/21/19 - 11:07 pm

clinical trials

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

Yahoo/Benzinga

Sun, 05/19/19 - 03:59 pm

Bellerophon Therapeutics

Bicycle Therapeutics

Peloton Therapeutics

GSK and Novartis liniment marketing misled Australian consumers: court

Reuters

Sat, 05/18/19 - 08:46 pm

Upcoming events – Phase III data for Chiasma and Novartis

EP Vantage

Fri, 05/17/19 - 07:23 pm

clinical trials

multiple sclerosis

Commentary: Novartis CEO: Gene therapy offers hope of cures in one treatment, but US needs new pricing and payment model

CNBC

Fri, 05/17/19 - 07:21 pm

Alcon Beats Expectations Since its Split from Novartis

Medical Devices and Diagnostics Industry

Fri, 05/17/19 - 07:13 pm

Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead

Endpoints

Fri, 05/17/19 - 01:03 pm

Gilead Sciences

Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K

Endpoints

Wed, 05/15/19 - 10:31 am

Novartis' Sandoz does digital from back office to 'not just apps' therapeutics

Fierce Pharma

Tue, 05/14/19 - 05:04 pm

Novartis’ Gilenya proves superiority over glatiramer acetate in relapsing remitting MS

Pharmaceutical Business Review

Mon, 05/13/19 - 08:14 pm

Relapsing Remitting Multiple Sclerosis

Novartis vows to fight U.S. price-fixing claims against Sandoz unit

Yahoo/Reuters

Mon, 05/13/19 - 09:24 am

Pages